Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VOR Vor Biopharma Inc.

Post-Mkt 06-12 17:43:19 EDT

14.36

+0.27

+1.92%

盘后14.22

-0.14-0.97%

17:41 EDT

High14.83	Low14.07	Vol544.87K
Open14.09	D1 Closing14.09	Amplitude5.39%
Mkt Cap778.11M	Tradable Cap627.68M	Total Shares54.19M
T/O7.87M	T/O Rate1.25%	Tradable Shares43.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VOR","market":"US","secType":"STK","nameCN":"Vor Biopharma Inc.","latestPrice":14.36,"timestamp":1781294400000,"preClose":14.09,"halted":0,"volume":544874,"hourTrading":{"tag":"盘后","latestPrice":14.22,"preClose":14.36,"latestTime":"17:41 EDT","volume":1165,"amount":16729.119235000002,"timestamp":1781300509661,"change":-0.14,"changeRate":-0.009749,"amplitude":0.009749},"delay":0,"changeRate":0.019162526614620267,"floatShares":43710400,"shares":54185600,"eps":-46.32986,"marketStatus":"Post-Mkt","change":0.27,"latestTime":"06-12 17:43:19 EDT","open":14.09,"high":14.83,"low":14.07,"amount":7873630.90338,"amplitude":0.053939,"askPrice":14.79,"askSize":5,"bidPrice":13.22,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-46.32986,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1781308800000},"marketStatusCode":4,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":14.09,"preHourTrading":{"tag":"盘前","latestPrice":14.4162,"preClose":14.09,"latestTime":"09:26 EDT","volume":1701,"amount":24353.851473,"timestamp":1781270776555,"change":0.3262,"changeRate":0.023151,"amplitude":0.012505},"postHourTrading":{"tag":"盘后","latestPrice":14.22,"preClose":14.36,"latestTime":"17:41 EDT","volume":1165,"amount":16729.119235000002,"timestamp":1781300509661,"change":-0.14,"changeRate":-0.009749,"amplitude":0.009749},"volumeRatio":0.655908,"impliedVol":1.3167,"impliedVolPercentile":0.2794},"requestUrl":"/m/hq/s/VOR/wiki","defaultTab":"wiki","newsList":[{"id":"2643213390","title":"Vor Biopharma shareholders back directors and governance measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2643213390","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643213390?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:39","pubTimestamp":1781296790,"startTime":"0","endTime":"0","summary":"The latest update is out from Vor Biopharma ( ($VOR) ). At its 2026 Annual Meeting, Vor Biopharma stockholders elected Andrew Levin, M.D., Ph.D., a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-shareholders-back-directors-and-governance-measures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-shareholders-back-directors-and-governance-measures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218866","title":"Vor Biopharma shareholders approved amended 2021 equity incentive plan at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218866","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218866?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:12","pubTimestamp":1781295147,"startTime":"0","endTime":"0","summary":"Vor Biopharma held its annual shareholder meeting on June 11, 2026.Shareholders backed an amended and restated 2021 equity incentive plan, updating the annual share reserve increase calculation to include pre-funded warrant shares.The plan change also provides for accelerated vesting of outstanding, unvested time-based awards upon an employee participant’s death, unless an award agreement says otherwise.Shareholders ratified Ernst & Young as independent registered public accounting firm for 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exch","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDLc87Kgt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642432634","title":"Vor Bio gains boost from telitacicept IgA nephropathy approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2642432634","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642432634?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:22","pubTimestamp":1780953745,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Vor Biopharma ( ($VOR) ). Vor Bio and its collaborator RemeGen Co., Ltd. reported on June 8, 2026, that China’s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vor-bio-gains-boost-from-telitacicept-iga-nephropathy-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vor-bio-gains-boost-from-telitacicept-iga-nephropathy-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641726482","title":"Vor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2641726482","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641726482?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:30","pubTimestamp":1780925414,"startTime":"0","endTime":"0","summary":"Vor Bio  and RemeGen said Monday China's National Medicinal Products Administration approved telitacicept to treat adults with Sjogren's disease.The approval makes it the first authorized treatment for the condition in China. The approval followed RemeGen's phase 3 trial, which demonstrated significant improvements in patient symptoms and systemic disease activity, the company said.RemeGen developed telitacicept to treat the chronic autoimmune condition, and Vor Bio maintains the sole rights to develop and market the therapy outside of Greater China, it added.Shares of the company were up 1.1% in Monday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641484652","title":"Vor Bio says China NMPA approves telitacicept for Sjögren’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2641484652","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641484652?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:35","pubTimestamp":1780922146,"startTime":"0","endTime":"0","summary":"China’s NMPA cleared telitacicept for adult Sjgren’s disease, marking the first regulatory approval for the indication.RemeGen will develop, secure approvals, commercialize in China; Vor Bio holds rights outside Greater China.Decision was supported by Phase 3 data showing significant ESSDAI reductions at Week 24; improvements in ESSPRI.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLcdj3lm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1064131003.USD","BK0239","688331","LU1064130708.USD","VOR","LU2488822045.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641048465","title":"Vor Bio says telitacicept wins China conditional approval for IgA nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2641048465","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641048465?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:35","pubTimestamp":1780922130,"startTime":"0","endTime":"0","summary":"China’s NMPA granted conditional clearance for telitacicept to treat adult IgA nephropathy, marking the first BAFF/APRIL-targeting therapy approved for IgAN.RemeGen developed the drug, will commercialize it in China; Vor Bio holds rights outside Greater China.Approval was backed by interim Phase 3 TELIGAN data showing a 59% UPCR reduction at Week 39, a 55% placebo-adjusted drop.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL5BtZ68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU1064130708.USD","LU2148510915.USD","BK4139","688331","BK0239","LU1064131003.USD","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641321484","title":"Telitacicept Receives Nmpa Conditional Approval for the Treatment of Iga Nephropathy in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2641321484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641321484?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:30","pubTimestamp":1780921801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUA2XGHM0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","LU1064130708.USD","LU2148510915.USD","BK4139","688331","BK0239","LU1064131003.USD","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641169696","title":"Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar","url":"https://stock-news.laohu8.com/highlight/detail?id=2641169696","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641169696?lang=en_us&edition=fundamental","pubTime":"2026-06-05 00:33","pubTimestamp":1780590809,"startTime":"0","endTime":"0","summary":"Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study. The phase 3 study called “A Multicenter, Randomized, Double-Blind, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vor-biopharmas-phase-3-sjogrens-trial-puts-telitacicept-on-investors-radar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vor-biopharmas-phase-3-sjogrens-trial-puts-telitacicept-on-investors-radar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4139","VOR","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640962240","title":"Vor Bio grants 61,050 stock options, 12,900 RSUs to new hires under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640962240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640962240?lang=en_us&edition=fundamental","pubTime":"2026-06-02 05:00","pubTimestamp":1780347640,"startTime":"0","endTime":"0","summary":"Vor Biopharma granted equity awards on June 1, 2026 to 10 new employees under its 2023 Inducement Plan.Awards include options for 61,050 shares; exercise price $14.57; 10-year term.RSUs cover 12,900 shares; vest over four years: 25% after 12 months; remainder quarterly over 36 months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL2yWyrk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4585","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","VOR","BK4139","LU2210150020.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640622109","title":"Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640622109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640622109?lang=en_us&edition=fundamental","pubTime":"2026-06-02 05:00","pubTimestamp":1780347600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA3FQX2C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636530003","title":"Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2636530003","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636530003?lang=en_us&edition=fundamental","pubTime":"2026-05-19 02:00","pubTimestamp":1779127200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 18, 2026 14:00 ET (18:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742886","title":"Vor Bio price target raised to $18 from $15 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742886","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742886?lang=en_us&edition=fundamental","pubTime":"2026-05-15 01:08","pubTimestamp":1778778490,"startTime":"0","endTime":"0","summary":"Wedbush analyst Martin Fan raised the firm’s price target on Vor Bio (VOR) to $18 from $15 and keeps a Neutral rating on the shares. The firm notes...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vor-bio-price-target-raised-to-18-from-15-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vor-bio-price-target-raised-to-18-from-15-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635484527","title":"Vor Biopharma Is Maintained at Neutral by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2635484527","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635484527?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:30","pubTimestamp":1778765400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 09:30 ET (13:30 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635169047","title":"Wedbush Adjusts Price Target on Vor Biopharma to $18 From $15, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635169047","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635169047?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:45","pubTimestamp":1778755556,"startTime":"0","endTime":"0","summary":"Vor Biopharma (VOR) has an average rating of buy and mean price target of $37.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635715505","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Halozyme (HALO) and Vor Biopharma (VOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635715505","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635715505?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:20","pubTimestamp":1778754044,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Staar Surgical (STAA), Halozyme (HALO) and Vor Biopharma (VOR). S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-staar-surgical-staa-halozyme-halo-and-vor-biopharma-vor-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-staar-surgical-staa-halozyme-halo-and-vor-biopharma-vor-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4581","BK4548","LU0053671581.USD","BK4139","STAA","VOR","BK4585","HCSG","BK4198","BK4137","BK4588","LU0128526141.USD","XBI","LU0029874061.USD","HALO","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787637","title":"Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787637","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635787637?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:57","pubTimestamp":1778677037,"startTime":"0","endTime":"0","summary":"Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 85.96 percent increase over losses of $(5.20) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52520854/vor-biopharma-q1-adj-eps-0-73-beats-0-78-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635878717","title":"Earnings Flash (VOR) Vor Biopharma Posts Q1 Net Loss $5.11 a Share, vs. FactSet Est of $0.78 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635878717","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635878717?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:51","pubTimestamp":1778676674,"startTime":"0","endTime":"0","summary":"Earnings Flash (VOR) Vor Biopharma Posts Q1 Net Loss $5.11 a Share, vs. FactSet Est of $0.78 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782178","title":"Vor Biopharma Q1 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782178","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782178?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:38","pubTimestamp":1778675924,"startTime":"0","endTime":"0","summary":"Vor Biopharma Q1 net loss widensOverviewU.S. biotech firm's Q1 net loss widenedR&D expenses fell yr/yr, mainly due to reduced spend on previous programs and lower headcountCompany ended Q1 with $491.5","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q0LQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782596","title":"Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782596?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA6RPQG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635825607","title":"Vor Biopharma Q1 Net Income USD -219.6 Million VS. Ibes Estimate USD -32.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635825607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635825607?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLX5E0FA0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VOR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vorbio.com","stockEarnings":[{"period":"1week","weight":-0.0161},{"period":"1month","weight":-0.1445},{"period":"3month","weight":0.0429},{"period":"6month","weight":0.1263},{"period":"1year","weight":2.2023},{"period":"ytd","weight":0.0772}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.114},{"period":"6month","weight":0.0821},{"period":"1year","weight":0.2268},{"period":"ytd","weight":0.0819}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.04043},{"month":2,"riseRate":0.6,"avgChangeRate":0.020325},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.093017},{"month":4,"riseRate":0,"avgChangeRate":-0.182481},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.222738},{"month":6,"riseRate":0.333333,"avgChangeRate":1.084644},{"month":7,"riseRate":0.2,"avgChangeRate":-0.043439},{"month":8,"riseRate":0.4,"avgChangeRate":0.001368},{"month":9,"riseRate":0.4,"avgChangeRate":-0.0543},{"month":10,"riseRate":0.6,"avgChangeRate":-0.046096},{"month":11,"riseRate":0.2,"avgChangeRate":-0.192554},{"month":12,"riseRate":1,"avgChangeRate":0.3146}],"exchange":"NASDAQ","name":"Vor Biopharma Inc.","nameEN":"Vor Biopharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vor Biopharma Inc.,VOR,Vor Biopharma Inc.股票,Vor Biopharma Inc.股票老虎,Vor Biopharma Inc.股票老虎国际,Vor Biopharma Inc.行情,Vor Biopharma Inc.股票行情,Vor Biopharma Inc.股价,Vor Biopharma Inc.股市,Vor Biopharma Inc.股票价格,Vor Biopharma Inc.股票交易,Vor Biopharma Inc.股票购买,Vor Biopharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}